Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults

References

• Blommaert A, Hanquet G, Willem L Use of pneumococcal vaccines in the elderly: an economic evaluation Health Technology Assessment (HTA). [Internet]. Brussels: Belgian Health Care Knowledge Centre (KCE), 2016. Report No.: 274. https://kce.fgov.be/en/publications/all-reports/use-of-pneumococcal-vaccines-in-the-elderly-an-economic-evaluation
   Google Scholar
• Conseil Superieur de la Santé. 2022. Vaccination antipneumococcique (adultes). [Internet]. Report No.: CSSN°9674. https://www.health.belgium.be/fr/avis-9674-vaccination-antipneumococcique-adultes
   Google Scholar
• Struyf T, Nuyts S, Tournoy J, et al. Burden of infections on older patients presenting to general practice: a registry-based study. Fam Pract. 2021;38(2):165–171. doi: 10.1093/fampra/cmaa105
   Web of Science ®Google Scholar
• Verhaegen J, Flamaing J, De Backer W, et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011. Eurosurveillance [Internet]. 2014;19(31): [[cited 2023 Mar 23]]. Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES2014.19.31.20869 doi: 10.2807/1560-7917.ES2014.19.31.20869
   Google Scholar
• Chen H, Matsumoto H, Horita N, et al. Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep. 2021;11(1):11865. doi: 10.1038/s41598-021-91234-y
   PubMed Web of Science ®Google Scholar
• De Foor J, Senterre C, Leclercq P, et al. Profile of hospitalised elderly patients in Belgium—analysis of factors affecting hospital costs. JEoA. 2020;15:100209. doi: 10.1016/j.jeoa.2019.100209
   Google Scholar
• Truyers C, Goderis G, Dewitte H, et al. The intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Med Inform Decis Mak. 2014;14(1):48. doi: 10.1186/1472-6947-14-48
   PubMed Web of Science ®Google Scholar
• Doherty TM, Connolly MP, Del Giudice G, et al. Vaccination programs for older adults in an era of demographic change. Eur Geriatr Med. 2018;9(3):289–300. doi: 10.1007/s41999-018-0040-8
   PubMed Web of Science ®Google Scholar
• Mamouris P, Henrard S, Molenberghs G, et al. Pneumococcal vaccination prevented severe LRTIs in adults: a causal inference framework applied in registry data. J Clinical Epidemiol. 2022;143:118–127. doi: 10.1016/j.jclinepi.2021.12.008
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50. doi: 10.1016/j.eclinm.2018.12.007
   PubMedGoogle Scholar
• Janssens A, Vaes B, Abels C, et al. Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry. BMC Public Health. 2023;23(1):1104. doi: 10.1186/s12889-023-15939-7
   PubMed Web of Science ®Google Scholar
• Méroc E, Fletcher MA, Hanquet G, et al. Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine. Microorganisms. 2023;11(7):1816. doi: 10.3390/microorganisms11071816
   PubMed Web of Science ®Google Scholar
• Shiri T, Khan K, Keaney K, et al. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329–1344. doi: 10.1016/j.jval.2019.06.011
   PubMed Web of Science ®Google Scholar
• Flamaing J, De Backer W, Van Laethem Y, et al. Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium. BMC Fam Pract. 2015;16(1):66. doi: 10.1186/s12875-015-0282-1
   PubMedGoogle Scholar
• Marbaix S, Peetermans WE, Verhaegen J, et al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLoS ONE. 2018;13:e0199427.
   PubMed Web of Science ®Google Scholar
• INAMI/RIZIV. Médicaments remboursables par l’assurance soins de santé [Internet]. 2022. [cited 2023 Sep 10]. Available from: https://webappsa.riziv-inami.fgov.be/SSPWebApplicationPublic/fr/Public/ProductSearch
   Google Scholar
• Mangen M-J, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–1416. doi: 10.1183/13993003.00325-2015
   PubMed Web of Science ®Google Scholar
• Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285–1295. doi: 10.1080/14737167.2022.2134120
   PubMed Web of Science ®Google Scholar
• Polistena B, Icardi G, Orsi A, et al. Cost-effectiveness of vaccination with the 20-valent pneumococcal conjugate vaccine in the Italian adult population. Vaccines. 2022;10(12):2032. doi: 10.3390/vaccines10122032
   Web of Science ®Google Scholar
• Cantarero D, Ocaña D, Onieva-García MÁ, et al. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine. 2023;41(36):S5342–5349. doi: 10.1016/j.vaccine.2023.07.016
   PubMed Web of Science ®Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125. doi: 10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Annemans L, Beutels P, Bloom DE, et al. Economic evaluation of vaccines: Belgian reflections on the need for a broader perspective. Value Health. 2021;24(1):105–111. doi: 10.1016/j.jval.2020.09.005
   PubMed Web of Science ®Google Scholar
• INTEGO. Intego database; unpublished data. [Internet]. www.intego.be
   Google Scholar
• Sciensano. Report National reference Centre Streptococcus pneumoniae [Internet]. https://sciensano.be/sites/default/files/streptoccuspneumoniae_2019_2019_nrc_rapport.pdf_
   Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24. doi: 10.1016/j.jinf.2012.02.017
   PubMed Web of Science ®Google Scholar
• Van Wilder L, Charafeddine R, Beutels P, et al. Belgian population norms for the EQ-5D-5L, 2018. Qual Life Res. 2022;31(2):527–537. doi: 10.1007/s11136-021-02971-6
   PubMed Web of Science ®Google Scholar
• Van Wilder L, Devleesschauwer B, Clays E, et al. The impact of multimorbidity patterns on health-related quality of life in the general population: results of the Belgian health interview survey. Qual Life Res. 2022;31(2):551–565. doi: 10.1007/s11136-021-02951-w
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-Infected adults. N Engl J Med. 2010;362(9):812–822. doi: 10.1056/NEJMoa0903029
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–1348. doi: 10.1056/NEJMoa035060
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clinical Infectious Diseases [Internet]. 2018 [cited 2023 Mar 23]. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy312/5000157
   Google Scholar
• Olsen J, Schnack H, Skovdal M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ. 2022;25(1):1240–1254. doi: 10.1080/13696998.2022.2152235
   PubMed Web of Science ®Google Scholar
• Malene MB, Oyvind H, Tor M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Eff Resour Alloc. 2023;21(1):52. doi: 10.1186/s12962-023-00458-4
   PubMed Web of Science ®Google Scholar
• Cellule Technique (INAMI/SPF Santé Publique). Cellule Technique de traitement de données relatives aux hôpitaux [Internet]. 2020. [cited 2022 Mar 20]. Available from: https://tct.fgov.be/webetct/etct-web/national_data?lang=fr&menuSelected=apr_drg&selectedSideMenu=default&reset=true
   Google Scholar
• Beutels P, Blommaert A, Hanquet G, et al. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood. [Internet]. 1st. BE: Belgian Health Care Knowledge Centre (KCE); 2011. [cited 2023 Mar 23]. Available from: doi: 10.57598/R155C
   Google Scholar
• Statbel. Consumer health index [Internet]. Brussels; 2023 [cited 2023 Jul 12]. Available from: https://statbel.fgov.be/en/themes/consumer-prices/health-index
   Google Scholar
• Cleemput I. Belgian guidelines for economic evaluations and budget impact analyses [Internet]. 2nd ed. BE: Belgian Health Care Knowledge Centre (KCE); 2012. [cited 2023 Mar 23].doi: 10.57598/R183C
   Google Scholar
• Hoshi S, Shono A, Seposo X, et al. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022;40(49):7057–7064. doi: 10.1016/j.vaccine.2022.10.010
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79. doi: 10.1136/thx.2009.129502
   PubMed Web of Science ®Google Scholar
• Wang C-C, Peng C-L, Wang G-J, et al. Pneumococcal pneumonia and the risk of acute coronary syndrome: a population-based cohort study. Int J Cardiol. 2013;168(4):4480–4481. doi: 10.1016/j.ijcard.2013.06.134
   PubMed Web of Science ®Google Scholar
• Hughes GJ, Wright LB, Chapman KE, et al. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144(12):2654–2669. doi: 10.1017/S0950268816000856
   PubMed Web of Science ®Google Scholar
• Averin A, Shaff M, Weycker D, et al. Mortality and readmission in the year following hospitalization for pneumonia among US adults. Respir med. 2021;185:106476. doi: 10.1016/j.rmed.2021.106476
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. PharmacoEconomics. 2016;34(3):227–244. doi: 10.1007/s40273-015-0335-2
   PubMed Web of Science ®Google Scholar
• Løchen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2020;26(1):60–70. doi: 10.1016/j.cmi.2019.04.026
   PubMed Web of Science ®Google Scholar